Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Q3 2022 Earnings Presentation
13 slides from Therapeuticsmd's earnings presentation, Nov 14, 2022
Slide 1: Building the Premier Women's Health Company - Q3 2022 Earnings
Building the Premier Women’s Health Company Q3 2022 Earnings November 14, 2022 FOR INVESTOR PRESENTATION PURPOSES ONLY.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, th
Slide 3: Q3 2022 Financial Overview
Q3 2022 Financial Overview FOR INVESTOR PRESENTATION PURPOSES ONLY. 3
Slide 4: Quarterly Revenue Trends
Quarterly Revenue Trends Quarterly Revenue (YoY) Q3-22 Highlights $30 ▪ Total net revenue decreased 18% in Q3-22 vs $25.4 Q3-21 as there was $1M of license sales in 2021 $25 $20.9 ▪ Total net product revenue decreased 13% in Q3-22 vs Q3-21 $20 ▪ ANNOVERA net revenue decreased 12% in Millions $15 Q3-
Slide 5: Financial Results: Comparison Q3 2022 to Q3 2021
Financial Results: Comparison Q3 2022 to Q3 2021 Comparison of Key Financial Statement Items [$1,000’s] Q3-22 Q3-21 ▪ In April 2022, $120M in proceeds from the vitaCare Balance Sheet(1) divestiture were used to paydown the debt. Cash $ 27,080 $ 104,801 ▪ Gross margin of 82% in Q3-22 shows improvemen
Slide 6: Q3 2022 Commercial Overview
Q3 2022 Commercial Overview FOR INVESTOR PRESENTATION PURPOSES ONLY. 6
Slide 7: ANNOVERA TRx Performance by HCP Segment
ANNOVERA TRx Performance by HCP Segment Significant growth occurring between Q222 & Q322 amongst approved specialties in non-vacant territories was nearly offset by a 31% decline in the Tele-Health population Q121 Q221 Q321 Q421 6,000 Q122 Q222 Q322 5,000 4,000 TRx 3,000 6,174 5,494 4,744 4,999 4,97
Slide 8: ANNOVERA Prescribers: Launch to Date
ANNOVERA Prescribers: Launch to Date 10,000 16,000 9,000 1,537 14,000 1,306 8,000 1,487 Cumulative Prescribers Cumulative Prescribers 12,000 1,409 7,000 1,274 10,000 1,300 6,000 1,554 1,309 5,000 8,000 1,409 1,439 4,000 13,520 8,147 6,000 1,554 12,033 10,759 6,738 3,000 1,514 9,459 1,439 5,184 4,000
Slide 9: IMVEXXY Monthly TRx
IMVEXXY Monthly TRx 45,000 40,000 35,000 30,000 25,000 TRx 20,000 15,000 10,000 5,000 0 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Month FOR INVESTOR PRESENTATION PURPOSES ONLY. Source: Symphony Metys – September 2022
Slide 10: IMVEXXY Quarterly TRx
IMVEXXY Quarterly TRx 140,000 120,000 100,000 80,000 TRx 60,000 117,499 108,233 113,308 109,317 99,743 97,881 91,268 40,000 20,000 0 Q121 Q221 Q321 Q421 Q122 Q222 Q322 Month FOR INVESTOR PRESENTATION PURPOSES ONLY. Source: Symphony Metys – September 2022
Slide 11: IMVEXXY Prescribers: Launch to Date
IMVEXXY Prescribers: Launch to Date 35,000 1,623 1,606 30,000 1,527 1,678 1,671 Cumulative Prescribers 25,000 1,764 2,156 20,000 15,000 30,473 32,079 27,268 28,946 23,833 25,597 10,000 21,677 5,000 0 Q121 Q221 Q321 Q421 Q122 Q222 Q322 Quarter Existing Rxers New Rxers FOR INVESTOR PRESENTATION PURPOS
Slide 12: BIJUVA Quarterly TRx
BIJUVA Quarterly TRx 35,000 30,000 25,000 20,000 TRx 30,838 31,877 30,707 15,000 29,165 27,302 28,563 26,828 10,000 5,000 0 Q121 Q221 Q321 Q421 Q122 Q222 Q322 Month FOR INVESTOR PRESENTATION PURPOSES ONLY. Source: Symphony Metys – September 2022
Slide 13: Q&A
Q&A FOR INVESTOR PRESENTATION PURPOSES ONLY. 13